Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
|Articles|November 2, 2001
- Pharmaceutical Technology-11-02-2001
- Volume 25
- Issue 11
Manufacturers Face Challenges and Regulatory Changes
Author(s)Jill Wechsler
Threats of bioterrorism generate new reulatory policies to protect the public against biological warfare.
Advertisement
Articles in this issue
almost 25 years ago
blankalmost 25 years ago
Truth in Outsourcingalmost 25 years ago
One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluationalmost 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited Part IIalmost 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement